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BLACKBEARD OR ALBERT SCHWEITZER:
RECONCILING BIOPIRACY
MAGGIE KOHLS*
Introduction
Imagine you are ten years old again, and you have discovered by trial and error that when
you rub your scraped knees with your mom's marigold flowers, your knees stop hurting and heal
quickly. You share this information with your friends and eventually with your children so that
it becomes a part of your family lore. Your best friend grows up to become a research chemist at
a prestigious international pharmaceutical company. She develops a process for extracting
Calendula officinalis from marigold seeds. Her company patents both the process and the
purified extract, which is an antiseptic, an anti-inflammatory agent, and a skin softener.'
Would you think you were entitled to any portion of the pharmaceutical company's
profits? If you grew up in the United States, probably not.
You grew up in a culture where patents were commonplace. Even without any formal
training in patent law, you have probably internalized the notion that no one gets credit for just
an idea; one gets a patent and any resultant profits only when one actually creates something
new.2 Nearly everyone has had the experience of thinking of an idea for a product, not taking
that idea any further, and eventually seeing something very similar on the market. To receive a
patent, an inventor must both conceive of an invention and develop a method to make it.
3
Bioprospectors are scientists who search remote regions of this planet in hopes of finding
new drugs and new foodstuffs from exotic plants and animals. The locations are often
dangerous, and there is no guarantee the research will reap any rewards. Some view these
researchers as modern day heroes, facing danger and financial loss in hopes of finding new cures
and new crops for humanity. Those who oppose this practice call the researchers "biopirates,"
but not every opponent defines "biopiracy" the same way.
1. The International Center for Technology Assessment, a Washington, D.C.-based
* Maggie Kohls is a 2006 JD Candidate at the Chicago-Kent College of Law. The author would like to thank
Chicago-Kent Adjunct Professor Valerie Neymeyer-Tynkov, of Counsel at Ladas & Parry, for her helpful comments
and criticism and Associate Dean Jim Chen, University of Minnesota James L. Krusemark Professor of Law, for his
relentless encouragement.
I Vitacost.com, http://www.vitacost.com/science/hn/Herb/Calendula.htm (last visited Nov. 29, 2006).
2 "Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or
any new and useful improvement thereof, may obtain a patent therefore." 35 U.S.C.S. § 101. "[Under] section 101 a
person may have invented a machine or a manufacture, which may include anything under the sun that is made by
man ..... " Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (citing Hearings on H. R. 3760 before Subcomm. No.
3 of the House Comm. on the Judiciary, 82d Cong., 1 st Sess., 37 (1951)). "The laws of nature, physical phenomena,
and abstract ideas have been held not patentable." Id.
3 Early U.S. patent law asked for a working model when possible, but current law does not. Bonito Boats v.
Thunder Craft Boats, 489 U.S. 141, 147 (1989). It is well settled that an invention may be patented before it is
reduced to practice. Pfaffv. Wells Elecs., 525 U.S. 55, 61 (1998).
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non-governmental organization (NGO), defines biopiracy as powerful corporations
exploiting the folk wisdom of indigenous peoples while providing little or nothing in
return.
4
2. Dr. Vandana Shiva, an activist from India, defines biopiracy as the patenting of
indigenous biodiversity-related knowledge.
5
3. The ETC Group, a Canadian-based NGO, defines biopiracy as the monopolization
of genetic resources and knowledge taken from farming communities and people that
have developed and nurtured those resources.
6
Older dictionaries do not define "biopiracy" at all. Two newer on-line dictionaries define
biopiracy as:
1. The commercial development of naturally occurring biological materials,
such as plant substances or genetic cell lines, by a technologically
advanced country or organization without fair compensation to the people
or nations in whose territory the materials were originally discovered.7
2. Biological theft; illegal collection of indigenous plants by corporations
who patent them for their own use.
8
Understanding that not all who cry "biopiracy" are seeing any given activity through the
same filter clarifies why ten to fifteen years into this debate, the global intellectual property
community has reached no consensus on whether biopiracy is a real problem or if it has a
solution. This paper gives an overview of the different biopiracy paradigms and clarifies why
the biopiracy opponents often seem to be making contradictory demands.
Part I will elaborate on the different definitions opponents have given for the term
"biopiracy" and explain the differing objectives of each particular group of opponents. Part II
will give examples of patents that the different groups opposed. Part III will discuss some of the
solutions each of the groups has offered. This paper will conclude by examining which
objectives an international patent system can and should address and offer solutions that will
satisfy some of the opponents without stifling research. The paper will posit that any solutions
must further the development of better food and medicine for all of humanity.
4 Bioprospecting, International Center for Technology Assessment,
http://www.icta.org/global/bioprospecting.cfm (2004).
5 Vandana Shiva, Stopping Biopiracy, ZNet Commentary, http://www.zmag.org/sustainers/content/ 1999-
09/6shiva.htm (Sep. 6, 1999).
6 Captain Hook Awards for Biopiracy 2006, ETC Group,
http://www.etcgroup.org/upload/publication/ 18/01 /etccom.2006hookfmal.pdf (last visited Nov. 29, 2006)
7 THE AMERICAN HERITAGE DICTIONARY OF THE ENGLISH LANGUAGE, (4th ed. 2004),
http://dictionary.reference.com/browse/biopiracy
8 WordNet 2.0, http://dictionary.reference.com/search (last visited Nov. 29, 2006).
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I. Biopiracy Opponents Have Conflicting Objectives.
Definitions of biopiracy derive from the initial objections of the biopiracy opponents.
Some definitions are expansive enough to include any non-native use of traditional folksongs,
crafts, and tribal insignia; some opponents object not only to the developed world's use of
traditional knowledge 9 but also to the developed world's introduction of modem agriculture or
medicine to "indigenous peoples."' 10 This paper restricts its focus to patents on products or
processes derived from "biological resources"'1 1 found in less developed regions. Folksongs,
crafts, and tribal insignia are subjects for a copyright discussion and will not be analyzed here. A
discussion on the morality of modernizing tribal communities is also beyond the scope of this
paper. Although membership in the various groups of biopiracy opponents no doubt overlaps,
the opponents fall into four main types.
The first set of biopiracy opponents act as advocates for indigenous peoples ("the
indigenous people bio-opponents") and believe indigenous communities deserve "equitable
benefit sharing" from the profits on any products developed from indigenous knowledge.
A second set of biopiracy opponents objects to removing samples of any plant that is
native to one region and modifying it to grow in another region. They believe each country has
sovereignty over its native "germplasm"' 12 ("the germplasm bio-opponents").
A third group believes some knowledge or some materials are sacred and should not be
patented or even researched ("the romantic bio-opponents"). This group includes those who
believe traditional knowledge belongs to a local shaman or at most to a local community and
such knowledge should remain secret from the rest of the world.
9 "Traditional knowledge" is "[k]nowledge gained through tradition or anecdote," WORDNET 2.0,
http://dictionary.reference.com/search (2003), or "[T]he ways and means by which individuals or communities
identify and improve genetic resources over time." Thomas Cottier, Marion Panizzon, Legal Perspectives on
Traditional Knowledge: The Casefor Intellectual Property Protection, 7 J. INT'L ECON. L. 371 (2004).
" The term "indigenous peoples" also has varying definitions: (1) "People whose ancestors inhabited a place or
country when persons from another culture or ethnic background arrived on the scene and dominated them through
conquest, settlement, or other means and who today live more in conformity with their own social, economic, and
cultural customs and traditions than with those of the country of which they now form a part. (Also: 'native
peoples' or 'tribal peoples.')" Global Biodiversity Assessment,
europa.eu.int/comm/researchlbiosociety/library/glossarylist en.cfm (last visited Mar. 10, 2006); (2) "people who
were originally in a place, people who have a long history of being in a particular place and who retain their identity
within a larger entity, state, or empire." Theresa M. Smith, Glossary, iws.ccccd.edu/tsmith/glossary.htm (last visited
Mar. 10, 2006); and (3) "Peoples who maintain a close and natural link to the ecosystems and depend on them...
for their daily subsistence." Chidi Oguamanam, Localizing Intellectual Property in the Globalization Epoch: The
Integration of Indigenous Knowledge, 11 IND. J. GLOBAL LEGAL STUD. 135, 169 FNI (2004).
11 "Biological resources" or "genetic resources" are "[a]ny material of plant, animal, microbial, or other origin
containing functional units of heredity [that is] of actual or potential value. Tomme Rosanne Young, Specific issues
for consideration in the elaboration of the IR: Limits to rights over genetic resources, the issue of derivatives,
International Expert Workshop on Access to Genetic Resources and Benefit Sharing,
http://www.canmexworkshop.com/ documents/papers/III.5d.4.pdf (last visited Mar. 17, 2006) (citing the CBD
definition).
12 "Germplasm" is "the protoplasm of the germ cells that contains chromosomes and genes." WordNet 2.0,
http://dictionary.reference.com/search (2003). The biopiracy opponents use "germplasm" interchangeably with
"biological resources."
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A fourth view is that traditional knowledge is already in the public domain, and no one
should receive a patent based on traditional knowledge ("the no-patents bio-opponents"). Some
no-patents bio-opponents would extend this prohibition to drugs and crops derived from
traditional knowledge or traditional crops.
A. The Indigenous People Bio-Opponents Want a Share of Profits
The indigenous people bio-opponents do not object to patenting products based on
traditional knowledge; they want to make sure a traditional knowledge holder benefits from
having shared that information with the patentee. They do not dispute that when a Western
13
pharmaceutical company creates a new product, improves a technique, or identifies a process
that makes a traditional medicine more effective, the Western company is entitled to a patent
because of its new process. 14 When traditional knowledge helped in the search for that process
or that medicine, indigenous people bio-opponents believe that the holders of the traditional
knowledge are entitled to a share of any profits the pharmaceutical company might make.15
Otherwise, the bio-opponents see the Western company as stealing from the indigenous people.
Large amounts of money are at stake. In 1995, the estimated worldwide market value of
pharmaceutical derivatives from indigenous peoples' traditional medicine was $43 billion, 16
nearly 13% of the total worldwide pharmaceutical market.17 Developing that worldwide
pharmaceutical market is not cheap or fast. Recent research by Joseph A. DiMasi of the Tufts
Center for the Study of Drug Development, a research group associated with Tufts University,
put the cost of developing a new drug at $802 million.18 The U.S. Food and Drug
Administration [hereinafter FDA] says nine of ten experimental drugs fail in clinical testing that
can cost millions of dollars.19 Moreover, because the current U.S. drug approval system requires
massive investments before a drug even reaches the testing stage of drug development, many
experimental drugs go untested in humans.20 The FDA approved only twenty new drugs in
2005.21 Newly approved drugs took an average of eight and a half years to earn FDA approval.22
Of those that do make it to market, only three often actually make a profit.2 3 Even if the FDA
13 Many see the debate as a North-South division, rather than East-West. "Western" is used here to invoke the
developed countries.
14 Shubha Ghosh, Traditional Knowledge, Patents, and the New Mercantilism (Part II), 85 J. PAT. & TRADEMARK
OFF. Soc'Y 885, 889 (2003).
15 Id. at 889.
16 Thomas J. Krumenacher, Protection for Indigenous Peoples and Their Traditional Knowledge: Would a
Registry System Reduce the Misappropriation of Traditional Knowledge? 8 MARQ. INTELL. PROP. L. REV. 143, 144
(2004); Lynn McClelland, Bioprospecting: Market Based Solutions to Biopiracy, 2004 UCLA J.L. & TECH
NOTES 8 at 1 (2004).
17 World Wide Pharmaceutical Market, IMS WORLD REVIEW, http://www.ims-
global.com/insight/world in brief/review99/year.htm (2004).
1" Diedra Henderson, FDA rules aim to speed drug tests and trim costs, BOSTON GLOBE,
http://www.boston.com/business/healthcare/articles/2006/01/13/fda-rulesaim tospeed drugtests and trim costs
(Jan. 13, 2006).
19 Id.
20 Id.
21 Id.
22 Id.
23 Doug Bandow, Demonizing Drugmakers, CATO INSTITUTE, http://www.cato.org/pub display.php?pub id 1334
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approves a drug for use in the U.S., drug companies still have to go through similar processes in
other countries to market the drugs overseas.24
A pharmaceutical company might compare its eight and a half years of research and $802
million dollar investment to a tribesman's act of pointing out the tree bark that his tribe usually
uses to speed wound healing, and understandably ask, "Who took the risk? Who deserves the
reward?" Bioprospecting advocates interested in world health might compare the 2,000
members of a tribe who had access to some tree bark to the 6.6 billion people worldwide 25 who
have potential access after a pharmaceutical company did its research and understandably ask,
"Who deserves the reward?" Professor Jim Chen, Associate Dean of the University of
Minnesota Law School, emphatically wrote, "The harsh reality is that there is no economically
justifiable reason for protecting ethnobiological knowledge as property." 26 Spreading knowledge
of an organism's usefulness may be locally objectionable but is globally beneficial. 27
On the other hand, a pharmaceutical company might note that the chances of finding an
exotic plant with true medicinal properties are from one in 10,000 to one in 50,00028 and wisely
ask, "How can we make sure these people keep giving us their best information?" Granting
natives a share of profits may be a wise business decision. No conflict necessarily exists
between the goal of giving a share of the profits to the traditional knowledge holders and the goal
of better access to medicine for the whole world.
B. The Germplasm Bio-Opponents Say Removing Biological Resources from their Native
Country is Stealing Genes
A second group, the germplasm bio-opponents, does object to foreigners patenting
products or plant varieties derived from native species. The germplasm bio-opponents believe
that each country has sovereignty over its own native flora and fauna (germplasm). This group is
concerned not about benefits for indigenous people but about the actual material leaving the
country. When Monsanto patented a new wheat variety, India Resource Center, an Indian
activist group, called it "a clear case of theft" that would prevent Indian farmers from developing
their own breeds.29 Germplasm bio-opponents protest that when a transnational corporation
patents one variety of a crop, the corporation will force traditional farmers to buy the patented
seed or they will be subject to charges of infringement when they continue to grow native
seeds. 30 Germplasm bio-opponents object to "patenting public germplasm, the patrimony of all
(Nov. 29, 2006).
24 Within months of the FDA's approval of Abbott's new drug Kaletra that can withstand Africa's equatorial heat,
AIDS groups were complaining that Abbott was not providing it immediately at no profit to 117 needy countries.
David Greising, No winners in drugfight, CHICAGO TRIBUNE (Mar. 26, 2006). Citing the need to get regulatory
approval in Europe and each individual African country, Abbott's CEO Miles White said this fight with activists fell
"into the category of no good deed goes unpunished." Id.
25 David Levine, Current Population, http://www.ibiblio.org/lunarbin/worldpop (Mar. 14, 2006).
26 Jim Chen, Biodiversity and Biotechnology: A Misunderstood Relation, 2005 MICH. ST. L. REv. 51, 78 (2005).
27 Id. at 78.
21 McClelland, supra note 16, at 1.
29 Nidhi Nath Srinivas, Monsanto Patents Indian Wheat Gene,
http://www.indiaresource.org/news/2003/4486.html (Jun. 30, 2003).
30 Uzma Jamil, Biopiracy: The Patenting Of Basmati By RiceTee, World Conservation Union,
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humanity.., by anyone." 31 The bioprospectors would counter that resources to feed the hungry
or cure humanity's ills belong to the whole world, not to one tribe because of the happenstance
of its geographic location.
C. The Romantic Bio-Opponents Believe Traditional Knowledge Should Be Kept Secret
The third group, the romantic bio-opponents, objects to taking both physical biological
resources and traditional knowledge from their native habitats. They object to any patents on
traditional knowledge because they object to commercializing it. Some communities or shamans
value the very secrecy of medical traditions,32 believing that only the shaman can use a certain
medicine, only for his people, and only in a long-established ritual . Others believe it would be
sacrilegious to share such knowledge with the outside world.34 Bioprospectors, on the other
hand, compare tribal secrecy to trade secrecy. Under U.S. law, once others know a trade secret,
as long as they obtained that knowledge "by fair and honest means," anyone can use the
information.3 5 When bioprospectors learn of a plant's use, they feel free to exploit it.
The romantic bio-opponents sometimes show an antagonism to technological
development. They are afraid Western influences threaten traditional social structures like the
family or village networks.
36
D. The No-Patents Bio-Opponents Believe Traditional Knowledge Belongs in the Public Domain
The fourth group, the no-patents bio-opponents, believes that patenting products based on
traditional knowledge shows a lack of respect for indigenous communities and the centuries of
work that went into developing traditional knowledge. This group does not object to anyone
using the knowledge, is not asking for shared benefits, and is not objecting to biological material
leaving its native country. This group objects to the patents themselves on either old knowledge
or on a life-form. The bioprospector would respond that without patentability, there is
insufficient incentive to find and develop food crops or medicine.
II. Bio-Opponents have Objected to a Wide Range of Patents.
The bio-opponents have different objectives and thus different objections, yet the
biopiracy literature excoriates the same ten to twelve patents time after time. Below are some
http://www.iucn.org/themes/ceesp/publications/art-mono/basmati.doc (Oct. 8, 1998).
Enola Bean Patent Challenged, ETC Group, http://www.etcgroup.org/article.asp?newsid-96 (Jan. 05, 2001)
(quoting Miguel Tachna Felix of the Agricultural Association of Rio Fuerte a farmers' association in northern
Mexico).
32 Ghosh, supra note 14, at 892-93.
33 ,id. at 893.
34 Nancy Kremers, Speaking with a Forked Tongue in the Global Debate on Traditional Knowledge and Genetic
Resources: Are U.S. Intellectual Property Law and Policy Really Aimed at Meaningful Protection for Native
American Cultures?, 15 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 1, 24 (2004).
35 Kewanee v. Bicron, 416 U.S. 470, 476 (U.S. 1974).
36 Ghosh, supra note 14, at 914. Presumably, those who rhapsodize about preserving traditional lifestyles are
overlooking the shorter life expectancy of primitive people and their interesting customs such as female
circumcision, infibulation, and child slavery. Where one observer might see the noble savage, another would see
human potential trapped in a primitive society with no chance for self-actualization.
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examples of different patents that the four groups of bio-opponents have opposed.
A. The indigenous people bio-opponents objected to the lack of benefit sharing from the
Biovigora and Hagenia products.
The indigenous people bio-opponents do not quarrel with the patentability of drugs
derived from traditional knowledge; they object to pharmaceutical companies using traditional
knowledge without compensating traditional knowledge holders. They objected to a U.S.
commercialization of Hagenia abyssinica as a treatment for cancer when Ethiopians had used
that plant for centuries as a medicine, but the U.S. researcher did not share any benefits from his
patent with the Ethiopians. 37 They objected to a Canadian company, Option Biotech, selling
Biovigora to enhance male sexual performance, even advertising that Biovigora is from a rare
spice used for centuries by African tribesmen to remain sexually active for life.38 Option Biotech
has patented the seeds of Aframomum stipulatum, obtained from the Congo.39 The seeds are
ground up with Kola and encapsulated to produce Biovigora. 40 The Canadian company has not
shared any profits with African tribesmen.
4 1
B. The germplasm bio-opponents objected to patenting rice and beans.
The germplasm bio-opponents are not so concerned with benefiting traditional
knowledge holders; they object to any international transfer of seeds or plants. When an
American company developed a type of Basmati rice that could grow in the United States, Indian
bio-opponents objected because they feared the U.S. would export its rice to India and hurt
Indian farmers. When an American plant breeder developed a type of Mexican bean that could
grow in the U.S., Mexican bio-opponents objected because they feared a loss of bean exports to
the U.S., hurting Mexican farmers.
Both Indian and Mexican bio-opponents understandably wanted to protect their own
farmers. The American patent holders also understandably wanted to help American farmers.
(1) Basmati Rice
Basmati rice provides four percent of India's export earnings. 42 Basmati is a long grain
rice with more than 400 varieties, traditionally grown in both India and Pakistan.
43
In 1992, RiceTec, a Texas company, received a patent for "novel rice lines and to plants
3 Jay McGowen, Four Multipurpose Medicinal Plants, Out of Africa: Mysteries of Access and Benefit Sharing, at
7-8, http://www.edmonds-institute.org/outofafrica.pdf (2006).
38 Jay McGowen, A Treatment for Impotence, Out of Africa: Mysteries of Access and Benefit Sharing, at 5,
http://www.edmonds-institute.org/outofafrica.pdf (2006).
39 Id.
40 Hedley Enterprises, Option Biotech Products, Biovigora, http://www.hedley.ca/option biotech.html (last visited
Nov. 21, 2006).
41 McGowen, supra note 38, at 5.
42 Ghosh, supra note 14, at 902.
43 id.
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and grains of these lines and to a method for breeding these lines." 44 Most of RiceTec's original
twenty claims described the starch index, the burst index, production per acre, height of the
plant, length of the seed, and a method of selecting a rice plant based on the starch index, burst
index, etc. 45 The Council of Scientific and Industrial Research in India [hereinafter CSIR]
challenged the rice patent. 46 They submitted prior art showing that the rice characteristics
claimed were already in use in this country because of Indian imports of traditional Basmati
rice.47 After reexamination, the USPTO disallowed all the physical characteristic claims.48 The
only surviving claims, 8, 9, 11, 12, and 13, refer to "a rice plant produced from [BAS 867, RT
1117, and RT 1121] seed having the accession number ATCC [7594, 75939, and 75940],"
respectively.
49
The Indian government, a strong advocate of geographical indications for food products,
claimed victory when the USPTO limited the number of claims granted to RiceTec. 50 RiceTec
still has a patent and can still call its rice Basmati.
(2) Enola Beans
In the early 1990s, Larry Proctor, president of the seed company POD-NERS, brought
back some field bean seeds from Mexico. 5 1 After at least two years and several generations of
selective breeding, Proctor developed a stable light yellow bean, which he named Enola after his
wife's middle name. 52 He received a patent53 and a Plant Variety Protection certificate. 54 The
patent claims the distinctive yellow color as grown for the first time in the United States; 55 the
PVP certificate is based on a deposit of seeds with the United States Department of
Agriculture.
56
Germplasm bio-opponents claimed biopiracy, 57 asserting, "Because of this bean
44 Abstract of U.S. Patent 5,663,484 (issued Sep. 2, 1997).
45 U.S. Patent 5,663,484 (issued Sep. 2, 1997).
46 Ghosh, supra note 14, at 905.
47 ,d. at 906. See also U.S. Patent 5,663,484 Reexamination Cert. (issued Jan. 29, 2002).
41 U.S. Patent 5,663,484 Reexamination Cert. (issued Jan. 29, 2002).
49 U.S. Patent 5,663,484 (issued Sep. 2, 1997). The seed lines were deposited with the "American Type Culture
Collection (ATCC)... in compliance with the Budapest Treaty on the International Recognition of the Deposits of
Microorganisms for the Purposes of Patent Procedure." Id.
50 Jinghua Zou, Rice and Cheese, Anyone? The Fight over TRIPS Geographical Indications Continues, 30 BROOK
J. INT'L L. 1141, 1168-69 (2005). As a nation of immigrants, the United States is opposed to geographical
indications. Many immigrants moved here and continued to make their traditional products using the traditional
name. See e.g.., Anheuser-Busch, Inc. v. Du Bois Brewing Co., 175 F.2d 370 (3d Cir. 1949).
51 Gillian N. Rattray, The Enola Bean Controversy: Biopiracy, Novelty and Fish-and-Chips, 2002 DUKE L. &
TECH. REV. 8, 2-3 (2002); Timothy Pratt, Patent on Small Yellow Bean Provokes Cry of Biopiracy, N.Y. TIMES
(Mar. 20, 2001) (quoting David Lee, Proctor's lawyer, claiming the beans date from 1991).
52 Rattray, supra note 51, at 3; Pratt, supra note 51.
53 U.S. Patent 5,894,079 (issued April 13, 1999).
54 PVP Certificate No. 9700027 (issued Jun. 30, 1999).
55 Rattray, supra note 51, at 3.
51 PVP Certificate No. 9700027 (issued Jun. 30, 1999).
57 Rattray, supra note 51, at 3; Whatever Happened to the Enola Bean Patent Challenge?, ETC Group,
http://www.etcgroup.org/upload/publication/41 /01 /genotypeenola05.pdf (Nov. 29, 2006) [hereinafter Enola Bean
Patent Challenge].
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alone.., export sales have dropped over 90%, also affecting the market for other non-yellow
beans. 58 "Farmers may be unable to grow the crops they have grown for generations without
first paying royalties to patent holders."
59
The ETC Group, an activist group from Canada (formerly known as RAFI - Rural
Advancement Foundation International60 ) takes credit for inspiring the International Center for
Tropical Agriculture (CIAT), a Columbia-based NGO, to file a reexamination request with the
USPTO objecting to the patent "just about everyone agrees is technically invalid.",61 The ETC
Group declared the patent was "morally unacceptable because it [was] predatory on the
knowledge and genetic resources of indigenous peoples and farming communities." 62 CIAT
claimed the bean variety was an "in trust" germplasm that must remain in the public domain.
63
The Enola bean sparked such controversy that the Wall St. Journal interviewed Proctor, the
WTO discussed his beans at a meeting in Geneva, 64 and a French film company visited his
offices and made a documentary film.
65
Despite the initial clamor, the Enola bean story abruptly disappeared from the press in
2002.66 POD-NER's single suit for patent infringement has been on hold, pending
67 68
reexamination of the patent. Meanwhile, POD-NERS has won every other case. In those
cases, POD-NERS did not sue for infringement of the patent; it sued for infringement of the
Plant Variety Protection certificate. 69
Although the ETC Group sees Proctor as a biopirate, Proctor sees himself as a traditional
plant breeder, trying to bring a better crop to farmers, and fighting against huge agribusinesses
58 Rattray, supra note 51, at 11; Erich Habian, Bean Biopiracy, Intellectual Property Rights for the Rich and the
Poor?, Vienna University of Economics and Business Administration, http://www.wu-
wien.ac.at/usr/h99a/h9950236/iprs/casestudies.htm (last visited Mar. 12, 2006).
59 Rattray, supra note 5 1, at 12.
60 Pratt, supra note 51. The ETC Group had sample Mexican beans tested, which they found to be identical to
POD-NERS' patented beans. Enola Bean Patent Challenge, supra note 57. Proctor said the tested beans were red
and brown, not yellow. Telephone Interview with Larry Proctor, Pres. POD-NERS, (Mar. 13, 2006).
61 Enola Bean Patent Challenge, supra note 57 ; Pratt, supra note 51.
62 Enola Bean Patent Challenge, supra note 57.
63 Habian, supra note 58.
64 Telephone Interview with Larry Proctor, Pres. POD-NERS, (Mar. 13, 2006).
65 Id.
66 Taran Rampersad, Whatever Happened to the Enola Bean?, KnowProSe.com,
http://www.knowprose.com/node/2284 (Jun 10, 2005).
67 Telephone Interview with Larry Proctor, Pres. POD-NERS (Mar. 13, 2006). In this case, Proctor sued Tutuli
Produce, an importer of Mexican beans. Pratt, supra note 51. POD-NERS, LLC v. Tutuli Produce Corp and
Rebecca Gilliland, CV 99-10172, 2001 U.S. Dist. LEXIS 25945 (C.D. Cal. 200 1) (granting motion for stay pending
resolution of J.E.M. AG Supply Inc. v. Pioneer Hi-Bred Int'l, Inc. and patent re-examination). Rebecca Gilliland,
owner of Tutuli Produce, said the patent did stop her from importing beans; she went from 6 million pounds in 1999
to nothing in 2000, because of the patent suit. A Bean of a Different Color, American RadioWorks,
http://americanradioworks.publicradio.org/features/foodpolitics/beans/3.html ((last visited Mar. 12, 2006).
68 Telephone Interview with Larry Proctor, Pres. POD-NERS (Mar. 13, 2006).
69 Id. "Varieties that are protected under the PVPA [Plant Variety Protection Act] can be sold or advertised for
seeding purposes only by the owner of the protection certificate." B. Eriker and M. A. Brick, The Plant Variety
Protection Act, Colorado State University Cooperative Extension Agriculture,
http://www.ext.colostate.edu/pubs/crops/00301.html (Feb. 08, 2006).
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bringing out genetically modified crops. 70 Proctor found that the yellow beans had deeper roots,
were hardier, and were more resistant to moisture than traditional beans. 71 Perhaps farmers
agree. POD-NERS has granted licenses to processors or elevators in nine states, who sublicense
to individual farmers, and recently signed an agreement with "the largest distributor in the
United States."
72
C. The Romantic Bio-opponents Objected to Commercializing a Sacred Plant and a Microbe
from a Sacred Place.
Although the romantic bio-opponents at first appear to be merely defending the religious
beliefs of indigenous peoples, they sometimes reveal an antagonism to technological progress
and a disdain for Western culture.
(1) Ayahuasca
In 1974, Loren Miller, owner of the U.S.-based International Plant Medicine Corporation,
received samples of a local ayahuasca vine from a tribe in Ecuador. 73 In 1986, Miller obtained a
U.S. plant patent for a variation of the ayahuasca, which he called "Da Vine." 74 The plant is a
powerful hallucinogenic and is believed to have medicinal properties. 75 Miller hoped he could
use ayahuasca in psychotherapy or as a treatment for cancer and angina pectoris.
76
In 1994, when the Coordinating Body of Indigenous Organizations of the Amazon Basin
[hereinafter COICA], an umbrella group from nine South American countries, learned of the
patent, they were furious, believing patenting the ayahuasca was sacrilegious. 77 COICA claimed
Miller's new variety was identical to local domesticated plants78 and worked with attorneys at
the Center for International Environmental Law (CIEL), a nonprofit Washington, D.C.-based
organization, to request a reexamination of the patent.79 In their request, CIEL argued that the
plant variety was not distinct and, further, that the plant was sacred to Amazon natives and that
the patent violated public policy and morality.
8 0
The USPTO invalidated the patent on the first reexamination in 1999,81 finding that
7' Telephone Interview with Larry Proctor, Pres. POD-NERS (Mar. 13, 2006).
1 A Bean of a Different Color, American RadioWorks,
http://americanradioworks.publicradio.org/features/foodpolitics/beans/2.html (last visited Mar. 12, 2006).
72 Telephone Interview with Larry Proctor, Pres. POD-NERS (Mar. 13, 2006).
73 Leanne Fecteau, The Ayahuasca Patent Revocation: Raising Questions about Current U.S. Patent Policy, 21
B.C. THIRD WORLD L.J. 69, 84 (2001).
74 Kremers, supra note 34, at 30; Fecteau, supra note 73, at 84; U.S. Patent PP5,75 1.
75 Maria Jimenez, Saving the 'Vine of the Soul,' Amazon SpiritQuest, http://www.biopark.org/peru/save-vine.html
(Jun 9, 2001).
76 Id.
77 Fecteau, supra note 73, at 85.
78 K-remers, supra note 34, at 30.
79 Fecteau, supra note 73, at 85.
80 Id. at 85-86. Fecteau argues that the patent should have been rejected because it was immoral to grant a
property right in a religious symbol. Id. at 87 and 102. A quick search on the USPTO website shows that many
design patents have been issued on the Christian cross. See e.g.., U.S. Design Patent D506,945.
81 U.S. Patent Office Admits Error, Cancels Patent on Sacred 'Ayahuasca" Plant, CIEL PRESS RELEASE,
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herbarium sheets in Chicago's Field Museum had described the same plant more than a year
before Miller's application.8 2 The USPTO reinstated Miller's patent on January 26, 2001, after
he found two botanists willing to help him distinguish Da Vine from earlier specimens of
ayahuasca. 83 Despite his fifteen-year legal battle, the patent is now expired, and Miller never did
find a commercial use for Da Vine.
84
The Kofan Indians from Columbia call ayahuasca "yage," and today Columbian shamans
are selling yage tea, making yage house calls, publishing a yage periodical, and holding yage
conferences.
85
(2) Thermophiles
Closer to home, in 1997, at the 12 5th Anniversary of Yellowstone Park, Vice President Al
Gore, Secretary of the Interior Bruce Babbitt, and Park Officials announced with pride an
Agreement with Diversa, a pharmaceutical company. 86 This agreement provided that Diversa
would study microbes living in the Park's hot springs and pay the Park $20,000 a year for the
privilege. 87 Diversa would also provide equipment and training to the Park worth $75,000 a
year 88 and pay the Park royalties of 50% to 10% from any commercial products developed from
any of the Park's biological resources.89 Under the Diversa agreement, all fees and royalties
would go straight to the Park, bypassing the federal government.9" Unused to dealing with
contracts and intellectual property issues, the Park Service had hired a Washington, D.C.-based
nonprofit consultant, the World Foundation for Economic Development, to help it devise the
agreement.
91
Bio-opponents called this biopiracy and sued to stop the agreement. 92 The opponents
held the agreement up in court for three years, until the U.S. District Court for the District of
Columbia decided in favor of the Park.93 Judge Lamberth noted that researchers had been
collecting microbial samples from Yellowstone since 1898, Yellowstone grants up to 300
research permits every year, and the Diversa agreement represented the first time anyone offered
http://www.biotech-info.net/ayahuasca.html (Nov. 4, 1999).
82 Fecteau, supra note 73, at 86. 35 U.S.C. § 102(b) states that inventions are not patentable if the same invention
was "described in a printed publication.., more than one year prior to the date of application for patent in the
United States."
83 Glenn Wiser, U.S. Patent and Trademark Office Reinstates Ayahuasca Patent, at 8, CIEL,
http://www.ciel.org/Publications/PTODecisionAnalysis.pdf (Jun. 25, 2001).
84 Maria Jimenez, supra note 75.
85 Id.
86 Edmonds Institute v. Babbitt, 93 F. Supp. 2d 63, 64 (D.D.C. 2000).
87 Id. at 71.
8' Holly Doremus, Nature, Knowledge and Profit: The Yellowstone Bioprospecting Controversy and the Core
Purpose ofAmerica's National Parks, 26 Ecology L.Q. 401, 410 (1999).
89 Edmonds, 93 F. Supp. 2d at 71.
9' Christopher Smith, Biopiracy in Yellowstone Park, THE SALT LAKE TRIBUNE (Nov. 9, 1997),
http://www.organicconsumers.org/Patent/yellowstn.html.
91 Id.
92 Id.
93 Edmonds, 93 F. Supp. 2d at 64.
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to share benefits with Yellowstone. 94
In the Yellowstone case, there were no indigenous peoples, no traditional knowledge, and
no removal of germplasm from a foreign country. Opponents admitted that the work would
cause no ecological harm 95 and was likely to produce scientific benefits for the general public
and economic benefits for the Park.96 However, the romantic bio-opponents believed
Yellowstone itself is a "secular shrine" and one of "nature's holiest temples," 97 and "commercial
science does not belong in the national parks." 98 Opponents believed the "Park Service's hunger
for funds [did not] justify overlooking the inspirational purposes of the parks." 99
As the D.C. court noted, none of the previous researchers shared any benefits with the
Park, and if the court voided the agreement, Diversa could continue to remove samples under its
permit with no obligation to pay the Park. 100 Opponents conceded that research into the
microbes living in the hot springs (thermophiles) was valuable but insisted commercial
exploitation was inappropriate.'10 Judge Lamberth noted that commercial research without
compensation to the Park has been ongoing for the last 100 years.
10 2
Romantic bio-opponents see indigenous peoples' traditional way of life as being "in close
harmony with the natural environment," stating, "These communities are the repositories of vast
accumulations of traditional knowledge and experience that links humanity with its ancient
origins. It is a terrible irony that as formal development reaches more deeply into rainforest,
deserts, and other isolated environments, it tends to destroy the only cultures that have proved
able to thrive in these environments." 
10 3
D. The no-patents bio-opponents objected to patents on neem and turmeric.
The no-patents-on-old-knowledge bio-opponents do not object to others' using traditional
knowledge or removing biological material from its native habitat; rather they object to patenting
products based on traditional knowledge. They believe traditional knowledge is in the public
domain, and because patents are for new inventions only, patenting such knowledge shows a lack
of respect for ancient wisdom. 35 U.S.C. § 102 does not recognize foreign oral traditions or
customs. 104 All foreign prior art must be in a written tangible form. Not much traditional
94 Id. at 71.
95 Doremus, supra note 88, at 456. "Only a tablespoon of fluid [is] needed to gather millions of microbes."
Smith, supra note 90.
96 Id. at 482.
97 Id. at 474.
98 Id. at 463.
99 Id. at 488.
100 Edmonds, 93 F. Supp. 2d at 71.
101 Doremus, supra note 88, at 402.
102 Edmonds, 93 F. Supp. 2d at 71.
103 Michael A. Bengwayan, Intellectual and Cultural Property Rights of Indigenous and Tribal Peoples in Asia, at
12, http://www.minorityrights.org/admin/Download/pdf/IntellPropRights2003.pdf (May 2003).
104 A person shall be entitled to a patent unless--
(a) the invention was known or used by others in this country, or patented or described in a printed
publication in this or a foreign country, before the invention thereof by the applicant for patent, or
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knowledge is written, allowing U.S. companies to obtain patents on plant uses that have been
around for centuries. Dr. Vandana Shiva, director of the New Delhi-based Research Foundation
for Science, Technology, and Ecology 10 5 and a foremost Indian no-patents bio-opponent, stated
that if § 102 is revised to recognize unwritten foreign prior art, "the world will have solved the
problem of piracy of indigenous knowledge."'
10 6
(1) Neem
Indians have used extracts from the neem tree for centuries as a pesticide, medicine, and
fertilizer.10 7 Originally native to India, the tree now grows in Australia, Africa, Fiji, Central
America, South America, Puerto Rico, and Hawaii. 1°8 Asserting that nothing based on
traditional knowledge should be patentable at all, the Research Foundation for Science,
Technology, and Environment, an Indian non-governmental organization, fought a European
patent issued to W. R. Grace. 109 The patent was for a "method of controlling fungi on plants by
the aid of a hydrophobic extracted neem oil." 110 After testimony from an Indian business that it
had been using neem for the same purpose years before W. R. Grace filed its patent
application, I ' the European Patent Office [hereinafter EPO] withdrew the patent grant in 2000,
finding it lacked novelty. 
112
(2) Turmeric
The CSIR in India (the same group that challenged the rice patent) raised similar
objections in 1995 against a U.S. patent on using turmeric to heal wounds.
Turmeric is a plant that grows throughout India and Pakistan. 113 The natives traditionally
boil the roots to extract a yellow powder to use as a dye, a cosmetic, condiment, and an ant
repellant.114 In 1995, two Indian-American scientists from the University of Mississippi, Suman
Das and Hari Cobly, received a patent "for the use of turmeric in wound healing.""11 5 Although
the patent discussed curcumin as possibly being the active ingredient in turmeric, it made no
claim for a process of isolating curcumin or purifying it. 116 The claims were simply for "[a]
(b) the invention was patented or described in a printed publication in this or a foreign country or in public
use or on sale in this country, more than one year prior to the date of the application for patent in the United
States.
105 Ronald Bailey, Dr. Strangelunch, REASON, http://www.reason.com/0101/fe.rb.dr.shtml (Jan. 2001).
106 Turmeric Patent is just the First Step in Stopping Biopiracy, Navdanya, http://www.navdanya.org/Articles (last
visited Apr. 13, 2006); Vandana Shiva, Biopiracy: need to change Western IPR systems, Service of Documentation
and Study on Global Mission, http://www.sedos.org/english/shiva.htm (Dec. 22, 1999).
107 Ghosh, supra note 14, at 910.
108 Id.
109 Id. Searching the USPTO website for "neem" shows 262 patents have been issued for some product or process
using neem, including thirteen assigned to W. R. Grace. http://www.uspto.gov (Mar. 14, 2006).
110 European Patent EP0436257.
111 K-remers, supra note 34, at 30.
112 Id.
113 Ghosh, supra note 14, at 898.
114 Id.
115 U.S. PatentNo. 5,401,504 (issued Mar. 28, 1995).
116 Id. One cannot obtain a patent on a naturally occurring substance, but under current U.S. patent office practice,
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method of promoting healing of a wound in a patient, which consists essentially of administering
a wound-healing agent consisting of an effective amount of turmeric powder to said patient,"
with additional claims for oral administration, for topical administration, for both topical and oral
administration, for when the wound was a surgical wound, and for when the wound was a body
ulcer."l 7 The same inventor received another patent for both oral and topical administration of
turmeric to treat acne.
11 8
A Quick Search of the USPTO website lists 576 patents involving "turmeric."'1 19 The
CSIR chose to fight this particular turmeric patent, asking the USPTO for a reexamination.
120
The Reexamination Certificate lists over thirty references not included in the original
application, showing that this use of turmeric was well known in the prior art. 12 1 On April 21,
1998, the USPTO cancelled all claims of the patent for the "Use of Turmeric in Wound
Healing."
Curiously, today the CSIR, which challenged the rice and turmeric patents, owns
seventeen European neem-based patents and four European turmeric-based patents.122
III. Suggested Resolutions Also Conflict with Each Other.
After reviewing the biopiracy opponents' list of issues, goals, or complaints, the reader
will understand that no single action will resolve all of them. Some efforts to please one group
have offended another. Those who believe traditional knowledge belongs in the public domain
will conflict with those who want to maintain its secrecy. Those who want to ensure shared
benefits to the traditional knowledge holders may conflict with those who want no patents to
issue on traditional knowledge.
In 1993, the World Intellectual Property Organization 123 [hereinafter WIPO] went on
fact-finding missions in 28 countries to identify the needs of traditional knowledge holders.1
24
one can obtain a patent on a substance by being the first to "isolate and purify" discovered substances. Linda J.
Demaine & Aaron Xavier Fellmeth, Reinventing the Double Helix: A Novel and Nonobvious Reconceptualization of
the Biotechnology Patent, 55 STAN. L. REV. 303,462 (2002). "It is not enough to merely isolate and purify the
substance; there also must be a use for the substance. For example, in Brenner v. Manson, Manson developed a
process for making certain steroids. But, at the time he discovered the process, Manson did not realize the utility of
the steroids he was producing. Therefore, the Court denied Manson's process patent application." Lester I. Yano,
Protection of the Ethnobiological Knowledge of Indigenous Peoples. 41 UCLA L. Rev. 443, 457 (1993).
117 U.S. Patent No. 5,401,504 (issued Mar. 28, 1995).
1I U.S. Patent No. 6,048,533 (issued Apr. 11,2000).
119 http://www.uspto.gov (last visited Mar. 14, 2006).
120 Ghosh, supra note 14, at 899.
121 35 U.S.C. § 102(a) denies patentability "if the invention was known or used by others in this country." If the
patent was known in another country, but never described in a printed publication, a U.S. patent can still be
obtained.
122 See http://ep.espacenet.com/ (searching for "Council Scientific Industrial" as applicant).123 "The World Intellectual Property Organization (WIPO) is an international organization dedicated to promoting
the use and protection ... intellectual property." About WIPO, http://www.wipo.int/about-wipo/en/ (last visited
Apr. 25, 2006). "With headquarters in Geneva, Switzerland, WIPO is one of the 16 specialized agencies of the
United Nations system of organizations." Id.
124 Intellectual Property and Traditional Knowledge, Booklet No. 2, World Intellectual Property Organization,
http://www.wipo.int/freepublications/en/tk/920/wipo pub 920.pdf (last visited Mar. 14, 2006) [hereinafter WIPO
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WIPO published a 340-page book detailing the results of its missions,125 concluding, "No single
template or comprehensive 'one-fits-all' solution is likely to suit all the national priorities and
legal environments, let alone the needs of traditional communities in all countries.'
126
In 2001, WIPO established the Intergovernmental Committee on Intellectual Property
and Genetic Resources, Traditional Knowledge and Folklore [hereinafter IGC] as an
international policy forum to continue research. 127 Realizing that indigenous peoples are not in a
position to travel to Geneva to testify, the IGC has held regional discussions and intellectual
property education meetings at various locations around the world. 128 However, WIPO's
members to date have not reached a consensus on how to treat indigenous knowledge as
intellectual property.
A. The indigenous people bio-opponents want to structure legal systems that will benefit
traditional knowledge holders.
The indigenous people bio-opponents have suggested indigenous people deserve some
kind of legal rights akin to patent protection so they can receive "equitable benefit sharing."
Since traditional knowledge of indigenous communities is not new, it is not patentable. Some
alternative suggestions have been:
1. Joint ownership of patent rights between those who provide traditional knowledge
and those who provide a patentable improvement.
2. A sui generis129 system according rights to traditional knowledge holders.
3. A worldwide registry of traditional knowledge.
4. Trustee systems in which trustees familiar with international intellectual property
laws would control the use of traditional knowledge and serve as negotiators for less
sophisticated communities, funneling profits to the communities.
5. Private contracts between companies and states or between companies and
individual communities.
(1) Joint Ownership
Some indigenous people bio-opponents have proposed joint ownership of the patent
rights to any product or process derived from traditional knowledge; that is, both the scientist and
Booklet].
125 INTELLECTUAL PROPERTY NEEDS AND EXPECTATIONS OF TRADITIONAL KNOWLEDGE HOLDERS: WIPO REPORT
ON FACT-FINDING MISSIONS ON INTELLECTUAL PROPERTY AND TRADITIONAL KNOWLEDGE (1998-1999) (200 1)
121 WIPO Booklet, supra note 124.
127 Id.
128 Kremers, supra note 34, at 50.
129 A system created specially for [a specific] purpose. Frequently Asked Questions about TRIPS,
http://www.wto.org/english/tratop e/trips e/ tripfq e.htm#Who'sSigned (last visited Mar. 14, 2006).
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the indigenous community would own the rights. 130 Some questions arise immediately when
considering this scheme. How does one identify a co-owner? Is it the individual tribesman who
worked with the researchers? Is it his entire village? Is it all the villages who share this
traditional knowledge? Can any of the villagers, as co-owners, license the patent without the
consent of the other owners?
A similar proposal would grant entire villages intellectual property rights in the
traditional knowledge itself. 131 Commercial use of traditional knowledge would require
compensation of the registered owner(s). 132 Similar questions arise under this scheme. What
kind of rights would be granted? How does one identify the rights holder if there are competing
villages? Once established, how long would these rights last? How would one register these
claims, and who would arbitrate or validate such claims? 133 How would this system be funded?
(2) Sui generis
Acknowledging that patent and copyright laws may not be applicable to traditional
knowledge, some commentators are calling instead for sui generis regimes. Several nations have
already adopted such systems, including Costa Rica, 134 Panama, Nigeria, Tunisia, and New
Zealand, along with the regional Andean Pact and Pacific Community nations.135 As with any
new system, the sui generis regimes are not all functioning as hoped.
For example, the 2001 Brazilian anti-biopiracy law 136 was intended to protect traditional
knowledge against "illegal exploitation" and required permission from indigenous and traditional
communities to use their biodiversity-related knowledge. 137 It also created a register to record
traditional knowledge and stated that protected communities are entitled to disclosure of origin in
any kind of publication related to a traditional knowledge, to receive the benefits from the
economic exploitation of their knowledge, and to prevent the access of unauthorized third
parties. 1
38
By 2003, Brazilian researchers were complaining that the law's restrictions were
hindering them. 139 Biologist Carlos Joly from the University of Campanis said it was
130 K-remers, supra note 34, at 38.
131 Cottier & Panizzon, supra note 9, at 388. See id. at 398 (recommending the rights vest in regional, national, or
international "bodies" and noting that 'good governance" would be needed to make the idea workable).
132 Id. at 389.
133 kechi Mgbeoji, Patents and Traditional Knowledge of the Uses of Plants: Is a Communal Patent Regime Part
of the Solution to the Scourge of Bio Piracy? 9 IND. J. GLOBAL LEGAL STUD. 163, 186 (2001) (stating that local
arbitration can resolve competing claims from different regions).
134 Eliana Torelly de Carvalho, Protection of Traditional Biodiversity-Related Knowledge: Analysis of Proposals
for the Adoption of a Sui Generis System, 11 MO. ENVTL. L. & POL'Y REV. 38, 45 (2003).
135 K-remers, supra note 34, at 44.136 Medida Provisoria No. 2.186-16 (PASSED Aug. 23, 2001), ACCESS TO GENETIC RESOURCES AND BENEFIT-
SHARING, Convention on Biological Diversity, HTTP://WWW.BIODIV.ORG/PROGRAMMES/SOCIO-
ECO/BENEFIT/MEASURE.ASPX?ID 6154 (LAST VISITED APR. 22, 2006).
13' De Carvalho, supra note 134, at 45.
138 Id.
139 Luisa Massarani, Brazil's biopiracy laws are stifling research, SCIENCE AND DEVELOPMENT NETWORK,
http//www.scidev.net/News (Jul. 21, 2003).
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"impossible to obtain authorization from the owners of all the [biological samples] before
starting [an] expedition." 140 In October 2003, Brazil modified its biopiracy act to allow research
but not for commercial purposes.141 In 2005, asserting that biopiracy was still rampant, Brazil
modified its biopiracy law again, defining ten offenses with associated penalties ranging from
$85 to $20 million. 142 As of May, 2006, the Brazilian government had issued only three
authorizations granting access to researchers on genetic resources. 143
Even before the enactment of Brazil's biopiracy act, Eliana Rodriguez, a Brazilian
botanist, signed agreements in 1999 with three Krao Indian villages to share royalties from any
commercial products she developed from her research in the Amazon. 144 An employee at the
Brazilian Indian Affairs Agency accused her of biopiracy; seven years later Rodriguez is still in
"legal limbo," unable to continue her research.145 U.S. State Department officials noted a similar
virtual moratorium on research in the Philippines as an unintended consequence of aggressive
regulation.
146
(3) Database Protection
Both joint ownership of patents and sui generis regimes need a method for registering or
recording who the traditional knowledge holder is and what she knows. Several theorists have
proposed placing traditional knowledge into databases. 147 Taking this step provides several
benefits beyond establishing ownership of the knowledge. The more such knowledge can be
documented, the better it can be preserved. Estimates are that one of the world's 6,000 to 8,000
languages becomes extinct every two weeks. 148 One could easily extrapolate that along with the
languages, much traditional knowledge is also being lost. Placing such knowledge in a database
can preserve it for the future. Documenting traditional knowledge makes it easier for modern
pharmaceutical companies or agronomists to use knowledge that was previously known only to a
few people and hard or even dangerous to acquire.
Many local databases have already been started. For example, the Tulalip Tribes in
North America have developed Storybase, a digital collection of traditional knowledge.149 Some
of that knowledge may be disseminated and some may be kept secret. 15 Different levels of
140 Id.
141 Wagner de Oliveira, Brazil eases restrictions on biodiversity researchers, Science and Development Network,
http://www.scidev.net/News (Nov. 12, 2003).
142 Wagner de Oliveira, Brazil gets tough on biopirates, Science and Development Network,
http://www.scidev.net/News (Jun. 22, 2005).
143 Gustavo Morais, Biodiversity x Intellectual Property, Remarks at AIPLA Spring Meeting (May 4, 2006)
(PowerPoint on file with author).
144 Terry Wade, Brazil Grapples with Jungle Piracy Dilemma, REUTERS FEATURES, http://www.grain.org/bio-
ipr/?id-473 (Mar. 15, 2006).
145 Id.
146 K-remers, supra note 34, at 45.
147 Ghosh, supra note 14, at 922.
141 Muhammad Habibur Rahman, With love for all languages, Ekushey Special,
http://www.thedailystar.net/suppliments/ekush04/index.html (Feb. 21, 2004).
149 WIPO Booklet, supra note 124.
150 Id.
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information require different access codes. 151
Not all holders of traditional knowledge want to give up their trade secrets. When
Ethiopia demanded that all traditional practitioners, in order to practice, must register and must
submit their traditional formulations for incorporation into a national database, many submitted
inaccurate information in order to protect their secrets. 152
(4) Trust Model
The trust model proposes that traditional knowledge be turned over to a trustee, such as a
government or a non-governmental organization, which would handle negotiations with
companies that want to use the knowledge. 153 This model presumes the trustee and the
knowledge holders have a mutuality of interests, a presumption that does not always hold true. 
154
(a) Government as Trustee - The Kanis and Jeevani
The Tropical Botanical and Garden Research Institute in India [hereinafter TBGRI], the
largest botanical garden in Asia, 155 developed a preparation from an herb, arogyapaacha, which
the Kani forest people of southern India have been using for centuries. 156 Touted by many, the
Kani story is a good example of too many entities with conflicting good intentions. Eventually
seven governmental or non-governmental organizations were involved in some aspect of
producing Jeevani, the drug derived from arogyapaacha.
157
Around 18,000 Kani tribal people live in and around the forests of southern India. 158
They have gardens in front of their homes and cultivate small plots given to them by the Forest
Department. 159 Traditionally a combination chief, lawgiver, judge, physician, and priest led the
tribes. 16 Since India nationalized the forests, the chief s role is a token one, and the Forest
Department controls the Kanis' lives.161 They are extremely impoverished.162 Some do not have
huts; the huts that do exist were built years ago by the Forest Department.
163
In 1987, a team from the All India Coordinated Research on Ethnobiology, a
governmental agency set up by the Ministry of Environment and Forestry, 164 discovered the
151 K-remers, supra note 34, at 42.
152 Dr. Gerard Bodeker, Traditional Medical Knowledge, Intellectual Property Rights & Benefit Sharing, 11
CARDOZO J. INT'L & COMP. L. 785, 804-05(2003).
"' Ghosh, supra note 14, at 909.
154 Bodeker, supra note 152, at 807.
155 See Ani I Gupta, Value addition to local Kani tribal knowledge: patenting, licensing, and benefit-sharing,
http://www.iimahd.ernet.in/publications/data/2002-08-02AnilKGupta.pdf (last visited Mar. 16, 2006).
156 Ghosh, supra note 14, at 909.
157 Gupta, supra note 155.
151 Id. at 11.
159 Id.
160 Id.
161 Id.
162 Id.
163 Id.
164 Id.
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Kanis were eating arogyapaacha fruits to maintain energy.165 The Regional Research
Laboratory, a member of the All India team, isolated the active ingredients and developed a drug
derived from arogyapaacha. 166 Jeevani, as it came to be called, exhibited anti-stress, immuno-
stimulating, tumor control, anti-fatigue, and stamina-boosting properties. 1
67
The TBGRI conducted clinical trials on the drug and applied for a process patent in 1996,
because at that time India did not grant patents for pharmaceuticals. 1
68
Eventually the TBGRI, following guidelines the CSIR established, licensed
manufacturing rights to the Arya Vaidya Pharmacy, a private company manufacturing drugs
since 1948.169 The TBGRI helped to set up a trust fund, Kerala Kani Samudaya Trust Fund, to
distribute funds.170 The fund's first plan was to install a telephone booth in the Kattor area of
India. In 1999, the trust did distribute a portion of the Arya Vaidya Pharmacy money to three
tribes. 171 The Kerala Institute of Research Training and Development of Scheduled Caste and
Scheduled Tribes, a governmental agency, tried to convince the TBGRI that the Kanis should
manufacture Jeevani themselves. 172 The Integrated Tribal Development Programme, also a
governmental agency, set up a pilot program, paying fifty families 1000 Rupees ($22 U.S.) each
to cultivate the plant and supply the Arya Vaidya Pharmacy. 
173
The Arya Vaidya Pharmacy could not get enough raw materials and offered to pay the
Kanis directly, but the Forest Department refused to allow the rest of the Kanis to cultivate the
plants or collect the leaves because it was concerned with conserving the forest.174 By 2001, the
Kerala Forest Department allowed cultivation but demanded a share of the royalties.
175
Although the drug can be extracted from the leaves of the plant, which would allow completely
sustainable production, natives received no training, uprooted many whole plants, 176 and
overharvested the leaves. 1
77
By 2002, most of the governmental conflicts had been resolved, and each family earned
about 8,000 Rupees per year from the sale of leaves. 178 Meanwhile, in 1999, NutriScience, a
U.S.-based food supplement supplier, applied for a U.S. trademark on "Jeevani" for "dietary
supplements" but abandoned the application in 2001 after protests. 179 By that time, Great Earth
165 Id. at 14.
166 Id.
167 Id.
168 Id. at 17.
169 Id. at 9.
170 Id. at 24.
171 Id. at 22.
172 Id. at 6-8.
173 Id.
174 Id. at 24.
175 Bodeker, supra note 152, at 799; D. P. Agrawal, The Jeevani elixir of the Kani tribes of Kerala and their
intellectual property rights, http://www.infinityfoundation.com/mandala (2001).
176 Gupta, supra note 155, at 24.
177 Bodeker, supra note 152, at 799.17' T. Shiras Khan, Kani tribals reap financial benefits from wonderdrug Jeevani, Infochange Changemakers,
http://www.infochangeindia.org/changemakers 15.j sp (Oct. 2002).
179 D.P. Agrawal, supra note 175; U.S. Trademark App. No. 75692281 (filed Apr. 27, 1999).
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Companies, a Canadian company, had applied for a U.S. trademark on "Jeevani Jolt" for
"nutritional supplements;" Great Earth received its registration in March 2002.180 The Indian
process patent is expired, the TGBRI never applied for its own trademark on "Jeevani," and
some now estimate the Kanis are losing "billions of dollars."' 81 Arogyapaacha also grows in Sri
Lanka and Malaysia, but some believe only the species from the Kani's forest has the medicinal
properties. 182
(b) Government as Trustee - The San and Hoodia
The South African government established the Council for Scientific and Industrial
Research (CFSIR - not the same as the Indian council with a similar name) to help local
communities develop natural resources. The CFSIR investigated the Hoodia cactus, long used
by the San people as an appetite suppressant, thirst quencher, and awareness heightener.' 83 After
three decades,' 84 the CFSIR isolated and patented the active ingredient and sold the rights to
PhytoPharma, a British herbal manufacturer.185 PhytoPharma in turn sold the rights to Pfizer for
$21 million, which planned to introduce the new drug into the $6 billion diet market. 1
86
The CFSIR had not told the San about the research or about the deal with Pfizer. 187 The
San people sued the South African government, winning an agreement in 2002 that
acknowledged the work the government did in isolating the active ingredient but also provided
for benefit sharing with the San people. 1
88
For unspecified reasons, in July 2003, Pfizer withdrew from the project and the San are
now unlikely to see any benefit sharing. 189 None of those companies now selling Hoodia
products on the internet has any agreement with the San people.19
0
(c) The National Cancer Institute (NCI) as Self-Appointed Trustee
The NCI has developed a model contract for use with indigenous communities. 191 It has
a Letter of Collection agreement through which it uses U.S. contractors to collect plant
specimens in other countries.192 Each contractor is required to work with a local institution, such
... D.P. Agrawal, supra note 175; U.S. Trademark Reg. No. 2553741 (issued Mar. 26, 2002).
... P. A. Francis, Protecting lPR ofJeevani, Pharmabiz.com,
http://www.pharmabiz.com/article/detnews.asp?articleid-31587&sectionid-47 (Jan. 25, 2006).
182 Anil Gupta; WIPO-UNEP STUDY ON THE ROLE OF INTELLECTUAL PROPERTY RIGHTS IN THE SHARING OF
BENEFITS ARISING FROM THE USE OF BIOLOGICAL RESOURCES AND ASSOCIATED TRADITIONAL KNOWLEDGE,
http://www.wipo.int/tk/en (last visited Apr. 27, 2006).
183 Bodeker, supra note 152, at 795.
184 Chen, supra note 26, at 89.
185 Bodeker, supra note 152, at 796.
186 Id. at 795-96.
187 Kremers, supra note 34, at 30.
18' Bodeker, supra note 152,, at 796.
189 Chen, supra note 26, at 89-90.
19' J. Michael Finger and Philip Schuler, Poor People's Knowledge, p. 155,
http://www.worldbank.org/research/Poor Peoples Knowledge.pdf.
191 Bodeker, supra note 152, at 792.
192 McClelland, supra note 16, at 3.
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as a university in the country where the contractor is gathering specimens. 193 The university
receives screening results, training in NCI laboratories, and royalties from any successful
product.194 In exchange, the NCI retains the patent rights.195 When the University of Georgia
tried to use the NCI model contract in an agreement with Mexico and Mayan communities,
disputes arose between different Mayan communities, leading to protests that outsiders were
manipulating the Mayans.196 The University of Georgia eventually abandoned the project. 97
(5) Private Agreements
The indigenous people bio-opponents who want to acknowledge and compensate
traditional knowledge holders are not necessarily at odds with the best interests of the
pharmaceutical companies or agribusinesses that engage in bioprospecting. Many Western
businesses seem quite willing to help local communities. Because only one in 10,000 plants is
likely to have any medicinal properties, and an indigenous community's knowledge of how to
use which particular plant can save a pharmaceutical company years of wasted time, some multi-
national pharmaceutical companies have tried to share profits with an indigenous community.
Limited only by ingenuity, private companies are trying a variety of agreements with
governments and with individual communities.
(a) Merck and the Costa Rican Government
Merck & Co., Inc, a U.S.-based pharmaceutical company, entered into an agreement with
a Costa Rican governmental agency, INBio.198 Merck gave INBio an initial $1 million along
with $135, 000 worth of laboratory equipment, and agreed to give INBio one to three percent of
royalties received from any drugs Merck developed in Costa Rica in exchange for Merck
retaining the patent rights to such drugs.199 In turn, INBio is supposed to give half of those
royalties to the Ministry of Natural Resources, which is to use the money for conservation
projects.20 0 Merck will also build research facilities and train Costa Ricans.20 '
Detractors note that Costa Rica has an adult literacy rate of ninety-eight percent and has
had a stable government for the last 100 years. 20 2 As this is not typical for most developing
nations, critics say the Costa Rican model is not workable for most of the world.2 °3
(b) Natura Cosmetics and Brazilian tribes
Even companies with the best of intentions have had problems sharing benefits. Natura
193 Id.
194 Id.
195 Id.
196 Bodeker, supra note 152, at 792.
197 Id. at 792-93.
19' McClelland, supra note 16, at 2.
199 Id.
200 Id.
201 Id.
202 Id.
203 Id.
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Cosmetics SA, a Brazilian company that makes beauty products based on tropical plants, pays
rainforest communities for their help in selecting plants.20 4 It battled one community when
Natura wanted to install a sewage system, but the residents wanted a pickup truck (in an area
with few roads or service stations).20 5 In another community, one resident took all the money
from Natura's community fund, abandoned his wife and children, and moved away with another
woman.2 06 Undaunted, Natura continues to work with tribal groups and has developed a
Communities Relations Management program that defines the communities' needs.20 7 In 2006,
four communities and 670 families are supplying ingredients for the Natura Ekos line of
cosmetics.
2 08
(c) Private Ownership of the Rainforest
Noting that "in the fight against those who destroy their homeland and their botanical
resources, [indigenous] communities need the international clout of the biopirates on their side,"
Professor Paul Heald of the University of Georgia suggests pharmaceutical companies buy large
tracts of rain forest.20 9 Both indigenous communities and pharmaceutical companies have a
common enemy in the logging companies that are cutting down huge swatches of rain forest.
Even though we rely on giant pharmaceutical companies to find a pill for all our discomforts,
those companies have a huge public image problem. When a long-awaited medicine is
developed, critics are quick to complain that it costs too much.210 Believing that buying the
rainforest could save biodiversity and the pharmaceutical companies' public image with one
investment, Heald has gone so far as to write the advertising for them:
Last January, with help from the World Bank and the Brazilian government, we at Pfizer-
ADM-Genetech helped set aside 500 million aces of land in the Amazon basin to be kept
forever free from logging and industrial development. Was it merely to help a local
community maintain its way of life? [Insert footage of thriving village] Not entirely.
Was it to help insure [sic] that the "lungs of the world" would forever keep producing
oxygen? Only in part. Was it to help reduce global warming? We're glad to help, or
course, but we really had just one goal in mind: Discovering a cure for little Mary's
cancer [Insert footage of brave, sick child]. Phizer-ADM-Genetech [sic]: Your Friend in
the Rain Forest.
211
Only large transnational companies have the self-interest and the financial means to
ensure rainforest preservation.
204 Wade, supra note 143.
205 Id.
206 Id.
20' Natura Ekos: The Brazilian Biodiversity, http:/www.internethos.org.br (last visited Apr. 27, 2006).
208 Id.
209 Paul Heald, The Rhetoric ofBiopiracy, 11 CARDOZO J. INT'L & COMP. L. 519, 534 (2003).
210 See supra note 36.
211 Paul Heald, The Rhetoric of Biopiracy, 11 CARDOZO J. INT'L&COMP. L. 519, 541 (2003).Heald, supra note
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B. The no-patents bio-opponents want to structure a legal system that will forbid patents based
on traditional knowledge.
The no-patents bio-opponents, who do not object to using or marketing products based on
traditional knowledge but do object to patenting such products, have also made suggestions.
They want to change the current international patent regime to preclude patents based on
traditional knowledge. Their suggestions include:
1. Create databases of traditional knowledge to establish prior art.
2. Revise 35 U.S. § 102 to recognize unwritten foreign prior use and sale as prior art
3. Change TRIPS to forbid patenting of biological resources without prior consent of
communities and states and to grant community-owned intellectual property rights.
2 12
(1) Databases
Like the indigenous people bio-opponents, the no-patents bio-opponents recommend
establishing databases of traditional knowledge. Rather than to establish ownership of the
knowledge, the no-patents bio-opponents want the databases to establish the existence of the
knowledge. Once the knowledge is in a written form, it qualifies as prior art under 35 U.S.C. §
102, which requires that all foreign knowledge and foreign use must be demonstrated by a
writing. 213 Patent examiners can easily search such databases for prior art references.
The no-patents bio-opponents have begun compiling databases of their own. The Society
for Research and Initiatives for Sustainable Technologies and Institutions in India has developed
databases for local knowledge and advocates a global system.2 14 In a separate project, the
Government of India is recording all the national medicinal plant knowledge with the intent to
distribute the information to patent offices worldwide. 215 Based on the data entered by
December 2002, the Director of the National Institute of Science & Information Resources in
New Delhi asserted that 700-800 U.S. patents were "improperly based" on Indian traditional
knowledge.
216
The American Association for the Advancement of Science has created TEK*PAD, the
Traditional Ecological Knowledge Prior Art Database, an internet-accessible searchable database
on traditional uses of natural resources. 217 "TEK*PAD brings together and archives in a single
212 "The WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), negotiated in the
1986-94 Uruguay Round, introduced intellectual property rules into the multilateral trading system for the first time.
•. It establishes minimum levels of protection that each government has to give to the intellectual property of fellow
WTO members." Intellectual Property: Protection and Enforcement,
http://www.wto.org/english/thewto-e/whatis_e/tif e/agrm7_e.htm, (last visited Apr. 25, 2006).
213 But see generally Harold C. Wegner, Eisner: Judicial Drive to Eliminate Territoriality Limitations of Prior Art,
23 BIOTECHNOLOGY L. REv. 747 (2004) (discussing whether In re Eisner, which combined a non-enabling written
description with foreign sales to find a statutory bar, was a judicial revision of the 102 bars).
214 Bodeker, supra note 152, at 801.
215 Id. at 802.
216 Kremers, supra note 34, at 41.
217 See http://ip.aaas.org/tekindex.nsf/TEKPAD?OpenFrameSet (last visited Mar. 16, 2006).
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location, various types of public domain data necessary to establish prior art." 218
(2) Revise 35 U.S.C. § 102 to Recognize Traditional Knowledge
35 U.S.C. § 102(a) reads in part (emphasis added):
A person shall be entitled to a patent unless--
(a) the invention was known or used by others in this country, or patented or
described in a printed publication in this or a foreign country, before the invention thereof
by the applicant for patent, or
(b) the invention was patented or described in a printed publication in this or a
foreign country or in public use or on sale in this country, more than one year prior to the
date of the application for patent in the United States.
In other words, public use or public sale must take place in the United States. The only
foreign work recognized by U.S. patent examiners must be in a printed publication. Thus,
indigenous knowledge usually does not constitute prior art because it is not written down.
Even though existing law invalidated the turmeric patent, the "turmeric incident...
contributed to widespread criticism of U.S. patent examination procedures." 219 As the USPTO
points out, any party may submit evidence of prior art to the patent office, even anonymously,
before or after a patent issues.
220
Eliminating the written requirement on foreign prior art would affect only U.S. law, but
U.S. pharmaceutical companies are big players in the global utilization of indigenous knowledge
and changing this requirement could be a good public relations move for the United States. The
European Patent Office already considers foreign public use as prior art. 1 Because
pharmaceutical companies are not patenting native plants but rather processes and derivatives,
true innovations would still be patentable, the global community would still receive the benefits
of new drugs, and the no-patents bio-opponents would be satisfied.
(3) TRIPS
Dr. Vandana Shiva, an environmental biologist and activist from India, saw the turmeric
patent cancellation as a victory over "biopiracy" and urged India to revisit the TRIPS
agreement. 222 Shiva said TRIPS was forcing a global intellectual property regime on India with
no global recognition of prior art. 223 The no-patents bio-opponents recommend revising TRIPS
to:
1. Require prior informed consent of the state and the local community before
starting any research on biological resources.
218 Id.
219 K-remers, supra note 34, at 29.
220 K-remers, supra note 34, at 66-67.
221 Chen, supra note 26, at 85.
222 Ghosh, supra note 14, at 900.
223 Id.
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2. Require mandatory disclosure of source information in patent applications.
3. Forbid any patents on life forms including microorganisms.
224
4. Extend geographical indications beyond wine and spirits.
225
Prior informed consent and mandatory disclosure would give a type of intellectual
property right to the traditional knowledge holders because they could exclude others from
patenting the knowledge. A requirement for prior informed consent would be enforced the same
as any requirement to provide prior art information, namely, loss of the patent if an opponent
could show the research was done without consent.22 6 Anyone opposing the patent on these
grounds would have to prove fraudulent intent and show that the patent applicant knew of the
traditional knowledge. These procedures would take place after the patent issued.
Others go one step further and ask that proof of prior informed consent be included with
patent applications. 7 Without it, the patent should be denied. 8 Such a requirement would
allow indigenous groups to block the patent entirely or make demands for benefit sharing in
exchange for allowing the patent to issue.22 9 The question is still open as to who has the
authority to give consent.
Mandatory disclosure in biotechnological patent applications of any geographical source
and indigenous knowledge source would allow countries and communities to review patent
applications and file claims to block patents before grant.230 The United States delegation to
WIPO has opposed such mandatory disclosure.
231
The no-patents bio-opponents want to revise Article 27.3(b) of TRIPS, which allows
members to exclude plants and animals other than microorganisms from patentability but
requires that members provide some protection for plant varieties either by patents or by an
effective sui generis system. They want to exclude all patents on life forms.
232
No-patents bio-opponents also want to expand geographical indication protection enjoyed
by wines and spirits to cover food products that originated in specific regions. 233 They argue
other products have as much direct connection as, if not more than, wine and spirits to the region
224 Intellectual Property Rights, TRIPS AGREEMENT AND THE CBD, Third World Network,
http://www.twnside.org.sg/title/benefit.htm (Mar. 2001).
225 Article 23 of TRIPS agreement, World Trade Organization, http://www.wto.org/english/docs e/legal e/27-
trips.pdf (last visited Nov. 29, 2006).
226 Kremers, supra note 34, at 39-40.
227 Krumenacher, supra note 24, at 153.
228 Id.
229 Id. at 154.
230 Fecteau, supra note 73, at 100.
231 K-remers, supra note 34, at 146 n.321.232 Intellectual Property Rights, TRIPS AGREEMENT AND THE CBD, Third World Network,
http://www.twnside.org.sg/title/benefit.htm (Mar. 2001).
233 Sumathi Subbiah, Reaping What They Sow: The Basmati Rice Controversy and Strategies for Protecting
Traditional Knowledge, 27 B.C. INT'L & COMP. L. REV. 529, 549 (2004).
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in which they originate. 234 Not being able to use the traditional designation of the product, such
as jasmine rice, might reduce the economic incentive to take the biological resource and modify
to grow elsewhere. Some geographic indication protection is available in individual countries;
no-patents bio-opponents are seeking a worldwide protective system.
23 5
C. Neither the romantic bio-opponents nor the germplasm bio-opponents have any suggestions
for a reconciling legal system.
Both the romantic bio-opponents and the germplasm bio-opponents want to stop patents
on specific biological materials. Romantic bio-opponents cannot reconcile patent laws aimed at
disclosure with "perpetual and exclusive possession of... traditional knowledge."
236
Acknowledging that granting perpetual protection would keep useful knowledge from the rest of
the world, romantic bio-opponents consider that concession "a small price to pay."
237
Germplasm bio-opponents assert that patents on plant varieties "give legal monopoly rights over
plant genetic resources in way that restricts the flow of information and materials, threatening
plant breeding itself." 238 Neither group offered any reconciling suggestion.
IV. Will a Single Solution Work for Every Country and Every Community?
Because the different types of biopiracy opponents have different objectives, no one
solution will satisfy them all. To select any course of action, one needs first to identify a core
value that outweighs other values. For the purposes of this paper, the core value is curing human
ailments and feeding the world's hungry. Side benefits might be growth of a developing
country's economy, better living conditions for indigenous people, preservation of traditional
knowledge, and preservation of biodiversity, but the overriding goal is better food and medicine
for the whole world. Inasmuch as this paper is addressing intellectual property regimes that
maximize such progress, no attempt will be made to inquire into sacred values. Just as the U.S.
Federal Circuit and the USPTO have steered clear of decisions basing patentability on morality
since the Juicy Whip decision, 239 this paper will assume the international patent regime should
not make decisions based on the sacredness of plants or national parks.
Similarly, any attempt to stop germplasm at national borders is also beyond the scope of
this paper or of any patent system. Such attempts are also roughly 10,000 years too late.
240
Seeds disperse across national borders when birds, animals, winds, and rivers cross those
borders. 24 1 Nations have been exchanging and modifying crops since they started trading with
234 Id.
235 Id.
236 Kremers, supra note 34, at 23.
237 Mgbeoji, supra note 133, at 185.
238 Biopiracy by another name? A critique of the FAO-CIGAR trusteeship, Grain,
http://www.grain.org/seedling/seed-02-10-2-en.cfm (Oct. 2002).
239 Orange Bang, Inc. v. Juicy Whip, Inc., 185 F.3d 1364 (Fed. Cir. 1999). The Patent Act requires only that
products be "useful." See generally Mitchell Bros. Film Group v. Cinema Adult Theater, 604 F.2d 852, 860 (5th
Cir.-OLD 1979)
240 Jared Diamond, GUNS, GERMS & STEEL, 120 (W. W. Norton & Company 1999).
241 Id. at 115-116.
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each other. 242 Because not all native plants have equal nutritional value, growing crops
domesticated elsewhere is the only way the world is able to feed itself today.
243
Thus, we are left with reconciling the bioprospecting advocates, the indigenous people
bio-opponents, and the no-patents bio-opponents. There are three actions and one non-action
that will satisfy most of the objectives of these three groups and offend hardly any of them:
1. Do not revise TRIPS (the non-action).
2. Develop databases of traditional knowledge.
3. Encourage creativity in private solutions.
4. Revise 35 U.S.C. § 102 to allow unwritten foreign prior art.
A. TRIPS should remain a flexible framework that does not preclude any mutually agreeable
solutions.
As WIPO pointed out after exhaustive study, there is no one-size-fits-all solution. TRIPS
has some minimum patentability requirements but allows each individual state to enact its own
intellectual property legislation as long as it grants the same rights to all other members of the
TRIPS federation.24 4 Keeping TRIPS open and flexible allows member states to act as
"laboratories of experimentation," similar to the laboratory of the states theory of the United
States' federal government. 2 45 As it stands, TRIPS is flexible enough to allow private
experimentation, letting large companies negotiate with countries, NGOs, indigenous
communities, or individual shamans, and to allow legislative experimentation within states.
Innovative benefits-sharing and patentability plans will provide feedback on what works and
what does not, what is fair, and what is profitable.
As described above, few of the attempted solutions have worked perfectly. Working
through national governments did not give the San natives any benefits and even resulted in the
Western company pulling out of the deal. The Government-as-trustee model caused the Kanis to
lose benefits. Ignoring the traditional practices of the indigenous people caused offense to the
natives in Ecuador and Columbia. Trying to grant rights to one set of Mayans caused conflict
with another. Lack of training and supervision from the Western company resulted in over-
harvesting and damage to the Kanis' ecosystem. Invalidating the neem and turmeric patents did
not bring any benefits to developing nations or communities. Those solutions that showed the
most promise involved direct contracts with private companies, such Merck and Natura
Cosmetics.
Even though flexibility and experimentation are the keys to finding individualized
arrangements that protect indigenous people while encouraging research, TRIPS is necessary as
242 Id. at 120.
243 See generally Id.
244 Ghosh, supra note 14, at 886.
245 Id. at 887.
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a limiting framework. All members of the World Trade Organization [hereinafter WTO] are
automatically signatories to the TRIPS agreement. Through trade sanctions, only the WTO has
the power to force members to honor their agreements.
B. Private solutions should be encouraged
To continue bioprospecting and attain the goal of better food and medicine for the world,
transnational companies need both the continued cooperation of the native populations and the
long-term survival of biological diversity. No interests have a greater financial stake in
preserving biodiversity or the financial capacity to do so than the Western agribusiness and
pharmaceutical industries. Because private businesses are simply more creative than huge
government bureaucracies are and more far-sighted than isolated primitive villages are, private
solutions should be encouraged.
The idea described earlier of a large pharmaceutical company owning large portions of
the rainforest will no doubt offend some at first glance. However, the paper industry in the
United States illustrates the ecological benefit of private ownership of land. Due to the long-
term interests of the paper industry, national forestland has grown back to two-thirds of the
forestland that existed when Europeans first arrived, with four million new trees planted each
day.246 Large Western conglomerates do have more bargaining power than illiterate tribesmen
do, but those conglomerates have a long-term stake in making sure the information from the
tribesmen keeps coming and stays accurate. They also have a long-term stake in educating local
gatherers about sustainable agriculture to ensure a continuous supply of the necessary biological
products. Under the current tragedy-of-the-commons management, 200,000 acres of rainforest
are burned every day.
247
Convincing governments to sell large tracts of land to foreign corporations could present
a large hurdle. Creative corporations could negotiate long-term agreements or small
demonstration projects with recalcitrant governments. Limited projects might have a stronger
appeal to cautious companies reluctant to invest large sums with unstable governments. The
WTO with its capacity for trade sanctions could help ensure the contracts are enforced.
Details of private contracts must be allowed to vary and develop. Indigenous people bio-
opponents who are genuinely concerned about inequitable bargaining power can form private
negotiation facilitating organizations. The private company can serve as a watchdog on the
facilitator to make sure the facilitator itself does not end up with the profits. The facilitator can
ensure the natives are not shortchanged based on what they actually contribute. Although it will
be difficult to keep third world governments, eager to add to their own treasuries, completely out
of the negotiations, both the private companies and the facilitators can serve as watchdogs to
ensure the final agreements do not give too much to the governments and not enough to the
natives.
246 Frequently Asked Questions, Virginia's Sustainable Forestry Initiative Program,
http://www.sharplogger.vt.edu/virginiasfi/faq.html (last visited Apr. 24, 2006).
247 See generally LESLIE TAYLOR, THE HEALING POWER OF RAINFOREST HERBS (2004) (excerpted at
http://www.rain-tree.com/facts.htm) (asserting that less than 1 percent of [the rainforest's] millions of species have
been studied by scientists for their active constituents and their possible uses).
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The Western company will widely advertise every successful venture with an indigenous
community, both as a means to sell its new product and to better its public image. Each such
success will inspire a second and third Western company to emulate the first agreement and
perhaps offer an even better contract to the natives. Imagine Pfizer and Merck presenting
competing offers to the Kanis.
An unintended consequence of private contracts with indigenous peoples might be better
homes and schools and longer lives for the indigenous peoples themselves.
C. Databases are necessary now to preserve traditional knowledge.
As indigenous people integrate into modern society, much traditional knowledge will be
lost. Saving it before it disappears will provide information for future research and at the same
time, contribute to the stockpile of written prior art. The indigenous people bio-opponents, the
no-patents bio-opponents, and the bioprospecting advocates all agree that databases documenting
traditional knowledge are needed now to preserve such knowledge before it is lost forever.
Although they differ on the final use for such databases and on who should have access, they all
understand that as the world becomes industrialized, old ways will be forgotten. Even though
much traditional "knowledge" may eventually prove inaccurate, no way exists to separate the
valuable information from the useless if they are both lost.
Many separate organizations have already started databases. Whether a universal
database should be the final goal is not a question that needs to be resolved now. It is more
important that the work begin. To enter traditional knowledge into a database requires the
knowledge holders' willing input, awareness that such a thing as a database even exists, and
assurance that storing information does not destroy it or necessarily make it available to the
world. It also requires time and financial resources to program the structure of the database and
document the knowledge and requires computers and manpower to do the work. The groups that
have already started constructing their own databases are those sufficiently integrated into the
modern world to do so, such as the American Tulalips.
As with biological diversity, the entities with the greatest stake in preserving the
knowledge and with the financial capacity and work force to begin such an undertaking are the
Western pharmaceutical and agribusiness companies. Each company has an incentive to start
first and collect this information before its competitors do. The WTO should make sure no
government can erect any barriers to collecting this information.
D. It is time for the U.S. to revise its prior art definitions to acknowledge worldwide prior use.
When Congress wrote 35 U.S.C. § 102, communication from abroad took months, if not
years, and the restriction against recognizing foreign use and sale made sense to encourage
American inventors to find American solutions to problems. In an age of instant communication
and verification, this restriction no longer makes sense. As long as forty years ago, the
President's Commission on the Patent System, in its 1966 Report to the U.S. Congress,
recommended revising § 102 to include foreign use and sale as prior art.248 The proposed Patent
248 Fecteau, supra note 73, at 96. Congress amended 35 U.S.C. § 104 in 1993 and 1994 to recognize inventive
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Reform Act of 2006 also contains this change, revising 35 U.S.C. 102 by removing all references
to "in this country" and "in this or a foreign country," so that it would read simply:
(a) Novelty; Prior Art- A patent for a claimed invention may not be obtained if--
(1) the claimed invention was patented, described in a printed publication, or
otherwise publicly known--
(A) more than 1 year before the effective filing date of the claimed invention; or
'(B) 1 year or less before the effective filing date of the claimed invention, if the
invention was patented or described in a printed publication or otherwise publicly
known before the invention thereof by the applicant for a patent..."'
Today the EPO recognizes all worldwide prior art, not just European and not just printed.
WIPO requires mutual recognition of patent protections among all its members. U.S. companies
prosecute valuable patents globally, and commentators frequently speak of the possibility of
global patents. Saying "we honor all prior art" would be a good public relations move for the
U.S. intellectual property community, showing our willingness to be a part of a global
community.
Conclusion
As WIPO said, no solution will satisfy every group. What is important is to keep trying
and to maintain flexibility so that information is not lost and companies are not locked out of any
region that might have resources valuable to all of humankind. The goal is to feed and care for
humankind, and we can accomplish that without hurting any indigenous peoples.
activity in foreign countries that belonged to NAFTA or the WTO. 35 U.S.C.S. § 104 (2002).
211 S.B. 3818, 109th Cong. (2006).
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